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Abstract: Background: Depressive disorders are common in children and adolescents. Antidepressants,
psychotherapies, and their combination are often used in routine clinical practice; however, available
evidence on the comparative efficacy and safety of these interventions is inconclusive. Therefore, we
sought to compare and rank all available treatment interventions for the acute treatment of depressive
disorders in children and adolescents. Methods: We did a systematic review and network meta-analysis.
We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science,
PsycINFO, ProQuest, CINAHL, LiLACS, international trial registries, and the websites of regulatory
agencies for published and unpublished randomised controlled trials from database inception until Jan 1,
2019. We included placebo-controlled and head-to-head trials of 16 antidepressants, seven psychothera-
pies, and five combinations of antidepressant and psychotherapy that are used for the acute treatment of
children and adolescents (฀18 years old and of both sexes) with depressive disorder diagnosed according
to standard operationalised criteria. Trials recruiting participants with treatment-resistant depression,
bipolar disorder, psychotic depression, treatment duration of less than 4 weeks, or an overall sample
size of fewer than ten patients were excluded. We extracted data following a predefined hierarchy of
outcome measures, and assessed risk of bias and certainty of evidence using validated methods. Primary
outcomes were efficacy (change in depressive symptoms) and acceptability (treatment discontinuation
due to any cause). We estimated summary standardised mean differences (SMDs) or odds ratios (ORs)
with credible intervals (CrIs) using network meta-analysis with random effects. This study was registered
with PROSPERO, number CRD42015020841. Findings: From 20 366 publications, we included 71 trials
(9510 participants). Depressive disorders in most studies were moderate to severe. In terms of efficacy,
fluoxetine plus cognitive behavioural therapy (CBT) was more effective than CBT alone (–0·78, 95%
CrI –1·55 to –0·01) and psychodynamic therapy (–1·14, –2·20 to –0·08), but not more effective
than fluoxetine alone (–0·22, –0·86 to 0·42). No pharmacotherapy alone was more effective than psy-
chotherapy alone. Only fluoxetine plus CBT and fluoxetine were significantly more effective than pill
placebo or psychological controls (SMDs ranged from –1·73 to –0·51); and only interpersonal therapy
was more effective than all psychological controls (–1·37 to –0·66). Nortriptyline (SMDs ranged from
1·04 to 2·22) and waiting list (SMDs ranged from 0·67 to 2·08) were less effective than most active
interventions. In terms of acceptability, nefazodone and fluoxetine were associated with fewer dropouts
than sertraline, imipramine, and desipramine (ORs ranged from 0·17 to 0·50); imipramine was associ-
ated with more dropouts than pill placebo, desvenlafaxine, fluoxetine plus CBT, and vilazodone (2·51 to
5·06). Most of the results were rated as “low” to “very low” in terms of confidence of evidence according
to Confidence In Network Meta-Analysis. Interpretation: Despite the scarcity of high-quality evidence,
fluoxetine (alone or in combination with CBT) seems to be the best choice for the acute treatment of
moderate-to-severe depressive disorder in children and adolescents. However, the effects of these inter-
ventions might vary between individuals, so patients, carers, and clinicians should carefully balance the
risk-benefit profile of efficacy, acceptability, and suicide risk of all active interventions in young patients
with depression on a case-by-case basis.
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The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Zhou, Xinyu; Teng, Teng; Zhang, Yuqing; Del Giovane, Cinzia; Furukawa, Toshi A; Weisz, John R; Li,
Xuemei; Cuijpers, Pim; Coghill, David; Xiang, Yajie; Hetrick, Sarah E; Leucht, Stefan; Qin, Mengchang;
Barth, Jürgen; Ravindran, Arun V; Yang, Lining; Curry, John; Fan, Li; Silva, Susan G; Cipriani, Andrea;
Xie, Peng (2020). Comparative efficacy and acceptability of antidepressants, psychotherapies, and their
combination for acute treatment of children and adolescents with depressive disorder: a systematic review
and network meta-analysis. The Lancet Psychiatry, 7:581-601.
DOI: https://doi.org/10.1016/s2215-0366(20)30137-1
2
www.thelancet.com/psychiatry   Vol 7   July 2020 581
Articles
Comparative efficacy and acceptability of antidepressants, 
psychotherapies, and their combination for acute treatment 
of children and adolescents with depressive disorder: 
a systematic review and network meta-analysis
Xinyu Zhou*, Teng Teng*, Yuqing Zhang*, Cinzia Del Giovane, Toshi A Furukawa, John R Weisz, Xuemei Li, Pim Cuijpers, David Coghill, Yajie Xiang, 
Sarah E Hetrick, Stefan Leucht, Mengchang Qin, Jürgen Barth, Arun V Ravindran, Lining Yang, John Curry, Li Fan, Susan G Silva, Andrea Cipriani†, 
Peng Xie†
Summary
Background Depressive disorders are common in children and adolescents. Antidepressants, psychotherapies, and 
their combination are often used in routine clinical practice; however, available evidence on the comparative efficacy 
and safety of these interventions is inconclusive. Therefore, we sought to compare and rank all available treatment 
interventions for the acute treatment of depressive disorders in children and adolescents.
Methods We did a systematic review and network meta-analysis. We searched PubMed, Embase, the Cochrane Central 
Register of Controlled Trials, Web of Science, PsycINFO, ProQuest, CINAHL, LiLACS, international trial registries, and 
the websites of regulatory agencies for published and unpublished randomised controlled trials from database inception 
until Jan 1, 2019. We included placebo-controlled and head-to-head trials of 16 antidepressants, seven psychotherapies, and 
five combinations of antidepressant and psychotherapy that are used for the acute treatment of children and adolescents 
(≤18 years old and of both sexes) with depressive disorder diagnosed according to standard operationalised criteria. Trials 
recruiting participants with treatment-resistant depression, bipolar disorder, psychotic depression, treatment duration of 
less than 4 weeks, or an overall sample size of fewer than ten patients were excluded. We extracted data following a 
predefined hierarchy of outcome measures, and assessed risk of bias and certainty of evidence using validated methods. 
Primary outcomes were efficacy (change in depressive symptoms) and acceptability (treatment discontinuation due to any 
cause). We estimated summary standardised mean differences (SMDs) or odds ratios (ORs) with credible intervals (CrIs) 
using network meta-analysis with random effects. This study was registered with PROSPERO, number CRD42015020841.
Findings From 20 366 publications, we included 71 trials (9510 participants). Depressive disorders in most studies 
were moderate to severe. In terms of efficacy, fluoxetine plus cognitive behavioural therapy (CBT) was more effective 
than CBT alone (–0·78, 95% CrI –1·55 to –0·01) and psychodynamic therapy (–1·14, –2·20 to –0·08), but not more 
effective than fluoxetine alone (–0·22, –0·86 to 0·42). No pharmacotherapy alone was more effective than 
psychotherapy alone. Only fluoxetine plus CBT and fluoxetine were significantly more effective than pill placebo or 
psychological controls (SMDs ranged from –1·73 to –0·51); and only interpersonal therapy was more effective than all 
psychological controls (–1·37 to –0·66). Nortriptyline (SMDs ranged from 1·04 to 2·22) and waiting list (SMDs 
ranged from 0·67 to 2·08) were less effective than most active interventions. In terms of acceptability, nefazodone 
and fluoxetine were associated with fewer dropouts than sertraline, imipramine, and desipramine (ORs ranged from 
0·17 to 0·50); imipramine was associated with more dropouts than pill placebo, desvenlafaxine, fluoxetine plus CBT, 
and vilazodone (2·51 to 5·06). Most of the results were rated as “low” to “very low” in terms of confidence of evidence 
according to Confidence In Network Meta-Analysis.
Interpretation Despite the scarcity of high-quality evidence, fluoxetine (alone or in combination with CBT) seems to 
be the best choice for the acute treatment of moderate-to-severe depressive disorder in children and adolescents. 
However, the effects of these interventions might vary between individuals, so patients, carers, and clinicians should 
carefully balance the risk-benefit profile of efficacy, acceptability, and suicide risk of all active interventions in young 
patients with depression on a case-by-case basis.
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Introduction
Childhood and adolescence are risk periods for the 
development of psychiatric disorders, and major 
depressive disorder is a leading contributor to burden of 
disease in young people aged 10–24 years.1 In England in 
2017, major depressive disorder in children and 
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adolescents was common, with an estimated point 
prevalence of about 0·3% in children (5–10 years), 
2·7% in younger adolescents (11–16 years), and 4·8% in 
older adolescents (17–19 years).2 The course of this 
disorder is often characterised by heterogeneous symp­
toms (eg, irritability, aggressive behaviours, and school 
refusal), protracted episodes, frequent recurrence, and 
comorbid psychiatric disorders.3 Young patients with 
depression have more serious impairments in social and 
educational functioning and have an increased risk of 
smoking, substance misuse, obesity, and suicide com­
pared with adults with depression.4 Moreover, depression 
is the second or third leading cause of death in 
adolescence.4
In the past two decades, pharmacological and psycho­
logical interventions have been widely used in the 
treatment of depressive disorder in children and adol­
escents worldwide.5 In 2005–12, the prevalence of 
antidepressant use in children and adolescents increased 
from 1·3% to 1·6% in the USA and from 0·7% to 1·1% 
in the UK.6 As the first­line treatment, psychotherapies, 
especially cognitive­behavioural therapy (CBT) and 
interpersonal psychotherapy, appeared to be more 
effective compared with psychological controls in 
previous meta­analyses.7,8 The mean effects (standardised 
mean differ ence [SMD] –0·29) after treatment were 
more modest than those found for treatment of other 
youth problems, including anxiety (SMD –0·61), 
attention deficit hyper activity disorder (SMD –0·34), and 
conduct­related problems and disorders (SMD –0·46).9 
Previous meta­analyses10,11 have shown that anti depres­
sants, except for fluoxetine, do not offer a clear advantage 
over pill placebo for many individuals, and some 
antidepressants might increase risk of suicidality. The 
mean effects of antidepressants for major depressive 
disorder compared with pill placebo (Hedges g 0·21 for 
selective serotonin reuptake inhibitor [SSRI] and 0·16 for 
serotonin–norepinephrine reuptake inhibitor [SNRI]) 
have been more modest than those found for treatment 
of other youth problems, including anxiety disorder 
(Hedges g 0·71 for SSRI and 0·41 for SNRI) and 
obsessive­compulsive disorder (Hedges g 0·39 for 
SSRI).12
Whether the combination of antidepressant and 
psychological interventions is more beneficial than 
antidepressants alone remains unclear.13 The aim of this 
study was to synthesise all the available evidence on 
commonly used antidepressants, psychotherapies, and 
their combinations for the acute treatment of depressive 
disorder in children and adolescents.
Methods
Search strategy and selection criteria
In this systematic review and network meta­analysis, we 
updated the literature search from our two previous 
publications7,10 for the identification of trials of antidepres­
sants and psychotherapies monotherapy. We searched for 
eligible trials of combinations of antidepressants and 
Research in context
Evidence before this study
Antidepressants and psychotherapies are routinely used 
worldwide for the treatment of depressive disorder in children 
and adolescents. Several clinical practice guidelines recommend 
that psychotherapy should be considered as the first-line 
intervention for the management of depressive disorder in 
children and adolescents, whereas antidepressants are often 
reserved for more severe illness or when psychotherapy does not 
work or is not available. However, the evidence base has not been 
well established that psychotherapy is more effective and safer 
than antidepressants in the treatment of child and adolescent 
depressive disorder, and whether the combination of 
antidepressants and psychotherapies is more beneficial than 
antidepressants alone remains unknown. We searched for eligible 
trials of combinations of antidepressants and psychotherapy on 
PubMed, Embase, the Cochrane Central Register of Controlled 
Trials, Web of Science, PsycINFO, ProQuest, CINAHL, and LiLACS 
database for randomised controlled trials (RCTs) published from 
the date of their inception to Jan 1, 2019. Our two previous 
studies investigated the comparative efficacy and acceptability of 
14 antidepressants and nine psychotherapies for depression. No 
network meta-analysis has examined the relative effects of 
psychotherapies, pharmacotherapies, and their combination in 
the treatment of depressive disorder in children and adolescents.
Added value of this study
Our study provides the first comprehensive systematic review 
and network meta-analysis of all available RCTs, comparing 
any active interventions (antidepressant, psychotherapy, and 
their combination) with another or control conditions for the 
acute treatment of depressive disorders in children and 
adolescents. Our findings suggest that, in terms of efficacy, 
only fluoxetine plus cognitive behavioural therapy and 
fluoxetine alone were more efficacious than pill placebo, 
psychological controls and some active treatments for the 
acute treatment of depressive disorder in children and 
adolescents. In terms of suicidality, our findings confirmed 
that venlafaxine is associated with an increased risk of suicidal 
behaviour or ideation compared with pill placebo and ten 
other interventions.
Implications of all the available evidence
Fluoxetine (alone or in combination with CBT) seems to be the 
best choice for the acute treatment of moderate-to-severe 
depressive disorder in children and adolescents but the quality 
of evidence is low. Patients, carers, and clinicians should 
carefully balance the risk-benefit profile of efficacy, 
acceptability, and suicide risk of all active interventions in 
young patients with depression on a case-by-case basis.
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psychotherapy on PubMed, Embase, the Cochrane Central 
Register of Controlled Trials, Web of Science, PsycINFO, 
ProQuest, CINAHL, and LiLACS database for randomised 
controlled trials (RCTs) published from the date of their 
inception to Jan 1, 2019. We included studies comparing 
any active intervention (antidepressant, psychotherapy, 
and combination of antidepressant and psychotherapy) 
with any control condition or another active intervention 
for the acute treatment of children and adolescents 
(≤18 years old and of both sexes) with a primary diagnosis 
of depressive disorder, including major depressive 
disorder, dysthymia, and other specified types as defined 
by standard operationalised diagnostic criteria (Research 
Diagnostic Criteria, Schedule for Affective Disorders and 
Schizophrenia for School­Age Children—Present and 
Lifetime Version, DSM­III, DSM­III revised, DSM­IV, 
DSM­IV text revision, DSM­5, and ICD­10). The electronic 
database searches were supplemented with manual 
searches for published, unpublished, and ongoing RCTs in 
international trial registers (eg, ClinicalTrials.gov), web­
sites of drug approval agencies (eg, US Food and Drug 
Administration [FDA] website), key scientific journals and 
conference proceedings in the field, and reference lists of 
relevant trials or reviews appendix pp 3–17).14 We contacted 
study authors and drug manufacturers to request complete 
reports of the original papers or data from unpublished 
studies. There was no restriction on language.
We included any licensed oral antidepressants within the 
therapeutic dose range, including tricyclic antidepressants 
(amitriptyline, clomipramine, desipramine, imipramine, 
and nortriptyline), selective serotonin reuptake inhibitors 
(citalopram, escitalopram, fluoxetine, paroxetine, and 
sertraline), serotonin norepinephrine reuptake inhibitors 
(desvenlafaxine, duloxetine, and venlafaxine), and other 
drugs (mirtazapine, nefazodone, and vilazodone), 
as well as any manualised or structured psychotherapies, 
inclu ding behavioural therapy, CBT, family therapy, 
interpersonal psychotherapy, psychodynamic therapy, 
problem­solving therapy, supportive therapy, and others, 
regardless of the delivery format (eg, individual or group) 
or treatment medium (eg, face­to­face or online). We also 
included the combination of the above­mentioned anti­
depressants and psychotherapies. The pharmacological 
control condition was always a pill placebo, whereas the 
psychological control conditions were waiting list, treat­
ment as usual, and psychological placebo (appendix 
pp 18–20). For trials of antidepressants alone, we included 
only double­blind RCTs (patients and raters blinded). For 
trials of psychotherapy alone or the combination of 
antidepressant and psychotherapy, we included trials in 
which observers or raters were masked or participants 
were assessed by self­rating depression scales, because 
participants and therapists cannot be blinded.15,16 To reduce 
clinical heterogeneity, we excluded trials with quasi­
randomised design, treatment duration of less than 
4 weeks, and an overall sample size of fewer than ten 
patients. Trials involving patients with certain comorbid 
psychiatric disorders (eg, anxiety disorder or attention 
deficit hyperactivity disorder; appendix pp 21–24) were 
included, whereas trials that included participants with 
bipolar disorder, psychotic depression, depressive 
symptoms that did not meet the diagnostic criteria of 
depressive disorder, or treatment­resistant depression 
were excluded.
Two of four investigators (XZ, TT, YZ, and LY) inde­
pendently selected the studies, reviewed the main reports 
5670 records identified from trial registers
5488 titles excluded
182 reviewed in detailed screening
1 publication from trial registers
181 excluded
 61 had no standardised diagnosis  
 of depression
 54 trials in adults
 39 uncompleted studies
 17 had a non-blind design
 8 had a non-randomised design
 2 duplicates
390 full-text articles reviewed
71 randomised controlled trials included in the network meta-analysis*
 37 drug versus pill placebo
 25 active psychotherapy versus psychological control conditions
 8 active psychotherapy versus active psychotherapy
 7 drug versus drug
 5 combination therapy versus combination therapy
 4 drug versus combination therapy
 3 active psychotherapy versus combination therapy
 3 drug versus active psychotherapy
 1 combination therapy versus pill placebo
 1 active psychotherapy versus pill placebo
319 full-text articles excluded
 85 data on children or adolescents could not be extracted separately
 61 included patients without depression
 56 had no standardised diagnosis of depression
 47 had a non-randomised design
 26 duplicates
 17 were not original investigations
 17 had no available data
 10 had no relevant intervention




 3799 not original investigations
 2547 not RCTs
 1546 had no standardised diagnosis
 790 had a non-blind design
 172 trial in adults
 23 other publication from the 
 same trial 
9180 reviewed in detailed screening
86 records from 2 previous databases
 52 records from Zhou X et al 
  (2015)7
 34 records from Cipriani A et al 
  (2016)10
Figure 1: Study profile
*Descriptions are not mutually exclusive.
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and supplementary materials, extracted the relevant 
information from the included trials, and assessed the 
risk of bias (κ range for interrater reliability 0·87–0·90). 
Any discrepancies were resolved by consensus and 
arbitration by a panel of investigators within the review 
team (PX, AC, TAF, and PC). The full protocol of this 
network meta­analysis has been published.14 We assessed 
the studies’ risk of bias in accordance with the Cochrane 
Handbook for Systematic Reviews of Interventions.14 We 
assessed the confidence of evidence contributing to each 
network estimate using the Confidence In Network 
Meta­Analysis (CINeMA) software.17
Outcomes
Our primary outcomes were efficacy (depressive 
symptoms measured by mean overall change scores from 
baseline to after completion of treatment on stan dardised 
depressive symptom scales) and acceptability (all­cause 
discontinuation measured by the proportion of patients 
who withdrew from the study for any reason). All­cause 
discontinuation was used as a measure of the acceptability 
of treatments because it encompasses efficacy and 
tolerability.18 The secondary outcome was suicidality 
(measured by reported cases of suicidal behaviour or 
ideation). When depressive symptoms were measured 
with more than one standardised rating scale in the same 
trial, we used a predefined hierarchy (appendix p 26) 
based on psychometric properties and consistency of use 
across included trials.14 We established a hierarchy of 
informants of depressive rating scales, giving priority to 
those that were clinician­reported then those that were 
self­reported. We recorded the outcomes as close to 
8 weeks as possible for all analyses. If information at 
8 weeks was not available, we used data from 4–16 weeks 
(we gave preference to the timepoint closest to 8 weeks; 
if equidistant, we took the longer outcome).14
Data analysis
We did a pairwise meta­analysis in STATA (version 15.1)14 
and network meta­analysis in OpenBUGS (version 3.2.3)19 
using the random­effects model by summary stan­
dardised mean differences (SMDs, Cohen’s d) with 
95% CIs for continuous outcomes and odds ratios (ORs) 
with credible intervals (CrIs) for dichotomous outcomes. 
Missing continuous outcome data were analysed using 
the last available follow­up data, and missing dicho­
tomous outcome data were managed according to the 
intention­to­treat principle. Missing SDs were calculated 
from p values, t values, CIs, or standard errors.20 Further 
details about statistical analyses are provided in the 
published protocol.14
To assess transitivity, we compared the distribution 
of clinical and methodological variables (eg, age, sex, 
depressive severity at baseline, and treatment duration) 
that could act as effect modifiers across treatment com­
parisons.14 The variance in the random­effects distri­
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measure the extent of cross­study and within­comparison 
variability of treatment effects. A common estimate 
for the heterogeneity variance was assumed for all 
comparisons in the entire network, and we assessed the 
presence of statistical heterogeneity using the magnitude 
of the heterogeneity variance parameter (τ²) and total 
I² statistic. Incoherence between direct and indirect 
sources of evidence was statistically assessed globally, by 
comparison of the fit and parsimony of consistency and 
inconsistency models, and locally, by calculation of the 
difference between direct and indirect estimates in all 
closed loops in the network.21 The node splitting method, 
which separated evidence on a particular comparison into 
direct and indirect evidence, was used to calculate the 
inconsistency of the model.22 We estimated the ranking 
probabilities of being at each possible rank for each 
intervention. The treatment hierarchy was summarised 
and reported as surface under the cumulative ranking 
curve. To determine whether the results were affected by 
study characteristics, we did network meta­regression for 
primary outcomes according to the following variables: 
sex ratio, mean age, sponsorship, treatment duration, 
comorbid psychiatric disorder, risk of bias, sample size, 
rating scale, publi cation year, and mean baseline severity. 
We did pre specified sensitivity analyses for primary 
outcomes by omitting trials with unpublished data, trials 
with imputed data, trials with sample sizes smaller than 
20, trials with inconsistent treatment durations and 
selected time points, and trials with non­blinding 
assessment. We used comparison­adjusted funnel plots 
to assess publi cation bias.23
We fitted all models of network meta­analysis with 
uninformative previous distributions for the treatment 
effects. The codes for the network meta­analysis models 
are listed in the appendix (pp 27–37). In the network 
meta­analysis, we used group­level data; the normal 
likelihood for continuous outcomes and the binomial 
likelihood were used for dichotomous outcomes. Pooled 
estimates were obtained using the Markov Chains 
Monte Carlo method. Two Markov chains were run 
simultaneously with different arbitrarily chosen initial 
values. To ensure convergence, trace plots and the 
Brooks­Gelman­Rubin statistic were assessed.24 Statistical 
evaluation of inconsistency and production of network 
graphs and figures were done using the network 
and network graphs packages in STATA (version 15.1).25 
The appendix (p 39) lists the changes to the original 


































































Figure 2: Network of eligible comparisons
(A) Efficacy. (B) Acceptability. The width of the lines is proportional to the 
number of trials comparing every pair of treatments, and the size of each node is 
proportional to the number of randomly assigned participants. 
AMI=Amitriptyline. BT=Behavioural therapy. CBT=cognitive-behavioural 
therapy. CIT=citalopram. CLO=clomipramine. DYN=psychodynamic therapy. 
DES=desipramine. DEV=desvenlafaxine. DUL=duloxetine. ESC=escitalopram. 
FT=family therapy. FLU=fluoxetine. IPT=interpersonal therapy. IMP=imipramine. 
MIR=mirtazapine. NEF=nefazodone. NOR=nortriptyline. PST=problem-solving 
therapy. PAR=paroxetine. Pill PBO=pill placebo. Psy PBO=psychological placebo. 
SUP=supportive therapy. SER=sertraline. TAU=treatment as usual. 
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Reed et al 
(1994)











50% USA Not stated CDI (self-
reported); Not 
stated






Fine et al 
(1991)








30/36 12 (12) 13–17 (15·1) 83% Canada Outpatients CDI (self-
reported); 20·16 
(7·52)








DSM-IV-TR MDD CBT 
(12 sessions); 
waitlist
65/60 12 (12) 12–17 (Not 
stated)
54% Iran Outpatients CDI (self-
reported); 29·89 
(5·46)






Clarke et al 
(1999)















Curtis et al 
(1992)





12/11 8 (8) High school 
students 
(15·8)
89% USA School BDI-21 (self-
reported); 25·64 
(8·47)

















45/24 7 (7) 14–18 (16·2) 61% USA Not stated BDI-21 (self-
reported); 22·30 
(11·26)






Brent et al 
(1997)









13–18 (15·6) 76% USA Outpatients BDI-21 (self-
reported); 24·20 
(8·06)






Rossello et al 
(1999)








25/23/23 12 (12) 13–18 (14·7) 54% USA School CDI (self-
reported); 20·48 
(6·78)






Rohde et al 
(2004)
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(Continued from previous page)
Goodyer et al 
(2017)














11–17 (15·0) 75% UK Outpatients MFQ (self-
reported); 45·93 
(10·55)











CBT (9 sessions); 
psychological 
placebo
31/30 18 (18) 8–17 (12·7) 56% UK Not stated MFQ (self-
reported); 31·04 
(13·43)






Wood et al 
(1996)






26/27 Mean 9·2 
(9·2)/ Mean 
8·4 (8·4)
9–17 (14·2) 69% UK Outpatients MFQ (self-
reported); 27·28 
(10·75)






Clarke et al 
(2002)
































39/37 12 (12) 12–17 (15·4) 66% USA Not Stated QIDS-A-Pat (self-
reported); Not 
stated















20/23 16 (16) 13–17 (15·5) 84% USA Outpatients BDI-21 (self-
reported); 31·11 
(11·84)















32/25 24 (24)/39 
(39)
8–15 (11·8) 56% USA Not stated CDI (self-
reported); 11·06 
(7·85)






Trowell et al 
(2007)





















DSM-III-R MDD Family therapy 
(12 sessions); 
waitlist










Luby et al 
(2012)




27/27 12 (12) 3–7 (Not 
stated)
37% USA Outpatients BDI-21 (self-
reported); 12·60 
(8·49)
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67/67 22 (22) 7–14 (10·8) 56% USA Not stated CDRS-R (clinician-
reported); 53·59 
(11·37)






Israel et al 
(2013)













































29/13 14 (14) 7–12 (10·8) 67% USA Outpatients CDRS-R (clinician-
reported); 45·20 
(7·81)






Mufson et al 
(1999)





































Tang et al 
(2009)





35/38 6 (6) 12–18 (15·3) 66% China School BDI-21 (self-
reported); 32·48 
(9·31)






Eskin et al 
(2008)















BDI=Beck Depression Inventory. CBT=cognitive-behavioural therapy. CCMD-3=Chinese Classification of Mental Disorders third version. CDI=Children’s Depression Inventory. CDRS-R=Children’s Depression Rating Scale-Revised. DDNOS=Depressive 
disorder-not otherwise specified. DSRS=Depression Self-Rating Scale. FDA=US Food and Drug Administration. HAMD=Hamilton Rating Scale for Depression. K-SADS=Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children. 
MADRS=Montgomery-Asberg Depression Rating Scale. MDD=major depressive disorder. MFQ=Mood and Feelings Questionnaire. MinDD=minor depressive disorder. QIDS-A-Pat=Quick inventory of depressive symptomatology-adolescent version. 
RADS=Reynolds Adolescent Depression Scale. RDC=Research Diagnostic Criteria. SMFQ=The Short Moods and Feelings Questionnaire. *The method for transforming other depressive scales to CDRS-R.26
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DSM-IV MDD Fluoxetine plus 
CBT (10–20 mg/
day; 9 sessions); 
pill placebo plus 
CBT (9 sessions)
24/26 12 (12) 15–20 (Not 
stated)








March et al 
(2004)
DSM-IV MDD Fluoxetine plus 
CBT (10–40 mg/
day; 15 sessions); 
Fluoxetine 
(10–40 mg/day); 





















DSM-IV MDD Fluoxetine plus 
CBT (10–60mg/
day; 12 sessions); 
Fluoxetine 
(10–60 mg/day)









Riggs et al 
(2007)
DSM-IV MDD Fluoxetine plus 
CBT (20 mg/day; 
16 sessions); pill 
placebo plus CBT 
(16 sessions)











DSM-III-R MDD Imipramine plus 
CBT (3 mg/day 
per kg; 
8 sessions); pill 
placebo plus CBT 
(8 sessions)
















day; 12 sessions); 
Sertraline 
(25–100 mg/day 
per kg); CBT 
(12 sessions)
25/26/22 12 (12) 12–18 (15·3) 66% Australia Outpatients RADS (self-
reported); 84·24 
(13·21)






Deas et al 
(2000)
DSM-IV MDD Sertraline plus 
CBT 
(25–100 mg/day; 
12 sessions); pill 
placebo plus CBT 
(12 sessions)








(Table 3 continues on next page)
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companies funded 24 (33·8%) of 71 studies. We retrieved 
unpublished information for 11 (15·5%) of the 71 included 
trials. 32 trials (45·1%) were rated high on risk of bias, 
32 (45·1%) as moderate, and seven (9·9%) as low 
(appendix pp 49–53).
In terms of efficacy (70 RCTs, comprising 8906 patients), 
only fluoxetine plus CBT (SMD –0·73, 95% CrI 
–1·39 to –0·07) and fluoxetine (–0·51, –0·84 to –0·18) 
were more effective than both pill placebo and psycho­
logical controls (SMDs ranged from –1·73 to –0·83; 
figures 2A, 3, 4A; appendix pp 56–65). Fluoxetine plus 
CBT was more effective than CBT (SMDs –0·78, 95% CrI 
–1·55 to –0·01) and psychodynamic therapy (–1·14, 
–2·20 to –0·08); and interpersonal psychotherapy was 
more effective than all psychological controls (SMDs 
ranged from –1·37 to –0·66; figures 2A, 3, 4A; appendix 
pp 56–65). By contrast, nortriptyline (SMDs ranged from 
1·04 to 2·22) and waiting list (SMDs ranged from 
0·67 to 2·08) were worse than most active interventions.
In terms of acceptability (66 RCTs, comprising 
9075 patients), nefazodone and fluoxetine were asso­
ciated with fewer dropouts than sertraline, imipramine, 
and desipramine (ORs ranged from 0·17 to 0·50; 
figure 2B, 3, 4B). Imipramine was associated with more 
dropouts than pill placebo, desvenlafaxine, fluoxetine 
plus CBT, and vilazodone (ORs ranged from 2·51 to 5·06; 
figure 2B, 3, 4B).
Venlafaxine was associated with a significantly 
increased risk of suicidal behaviour or ideation compared 
with pill placebo (OR 8·31, 95% CrI 1·92–343·17) and ten 
other interventions (citalopram, escitalopram, fluoxetine, 
fluoxetine plus CBT, duloxetine, imipramine, family 
therapy, desvenlafaxine, CBT, and pill placebo plus CBT; 
ORs ranged from 5·07 to 18·98; figure 4C; appendix 
pp 67–69).
The median heterogeneity variances were estimated at 
0·49 (95% CrI 0·37–0·64) for efficacy and 0·32 
(0·04–0·61) for acceptability. The global I² values were 
56% for efficacy and 14% for acceptability. The assessment 
of transitivity showed most of the comparisons had 
variable baseline severity, mean age, sex ratio, and 
treatment duration. For example, one comparison of 
psychodynamic therapy with family therapy showed that 
it had a relatively long treatment duration of 36 weeks 
(appendix pp 70–72). The test of global incoherence 
showed a significant difference between the consistency 
and inconsistency models for efficacy (p<0·0001), but not 
for acceptability (p=0·5531; appendix p 74). Tests of local 
incoherence showed that the percentages for inconsistent 
loops were within the expected ranges based on the 
empirical data (six of 25 loops for the efficacy outcome 
and one of 24 for the acceptability outcome; 
appendix pp 74–77). The test of incoherence from the 
node­splitting model showed significant differences 
between some comparisons in efficacy and acceptability 
(appendix pp 78–81). The comparison­adjusted funnel 
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publication bias for efficacy outcome in psychotherapy 
trials, but not for acceptability (appendix pp 82–88).
Network meta­regression analyses showed that most 
modifiers (appendix pp 90) did not significantly affect the 
efficacy and acceptability of interventions; however, we 
found that studies in which participants had more severe 
depressive symptoms at baseline were associated with 
larger treatment effects, and that studies with high risk 
of bias were associated with a lower drop­out rate. These 
findings might result from the fact that most psycho­
therapy trials, which were assessed as high risk of bias 
due to non­blinding of performance and personnel, had 
relatively lower drop­out rates and baseline severity 
scores than the pharmacological trials (appendix pp 91–96). 
The sensitivity analyses did not materially affect the 
relative treatment effects (appendix pp 97–100). The 
ranking of treatments based on cumulative probability 
plots and surfaces under the cumulative ranking curve 
are presented in the appendix (pp 101–106). According to 
CINeMA, nine (12·5%) of 72 comparisons for the efficacy 
outcome were rated as low confidence of evidence and 
63 (87·5%) as very low, and for the acceptability outcome, 
one (1·3%) was rated as high confidence of evidence, 
three (4·0%) as moderate, 13 (17·3%) as low, and 
58 (77·3%) as very low (appendix pp 107–125).
Discussion
This updated analysis is based on 71 RCTs, which 
included 9510 children and adolescents with depressive 
disorders randomly assigned to 28 active interventions or 
four control conditions. To our knowledge, this is the 
first time that psychological intervention, pharma­
cological inter vention, and their combination for 
depressive disorder in children and adolescents have 
been compared in a network meta­analysis.
We found that, of all the included active interventions, 
only fluoxetine plus CBT and fluoxetine were significantly 
more efficacious than pill placebo in children and 
adolescents with depressive disorders. We also found that 
interpersonal psychotherapy was more efficacious than 
all psychological controls, but with very low confidence of 
evidence. Fluoxetine plus CBT was associated with a 
greater reduction in depressive symptoms than either 
CBT or psychodynamic psychotherapy, with very low 
confidence of evidence. Nortriptyline was worse than 
most active interventions; however, the interpretation of 
this result was limited by the inconsistent loop of 
nortriptyline versus fluoxetine versus pill placebo. These 
summary effect sizes were mostly medium to large with 
some uncertainty, which might result from the small 
number of patients included, and wide credible intervals. 
Thus, statistical indications of clinical superiority in this 
study should be interpreted cautiously.
Our findings in children and adolescents contrast 
with findings on the efficacy of antidepressants and 
psychological interventions in adults with major depres­
sive dis order, for whom all antidepressants were more 
efficacious than pill placebo27 and all psychotherapeutic 
interventions were superior to psychological control 
conditions.28 There are several possible explanations for 
this considerable difference. First, neurodevelopmental 
mechanisms, including robust changes in hormones 
and hormonal receptors in adolescent depression, could 
exacerbate emotional responses to negative social stimuli 
by dysregulation of the hypothalamic–pituitary–adrenal 
axis.29 Second, the smaller number of trials and smaller 
sample sizes for young patients with depression 
decreases statistical power for each comparison.30 Third, 
different design methods between adult and paediatric 
trials could lead to a higher placebo response rate in 
children and adolescents (45%) than adults (36%) based 
on clinician ratings, hindering the detection of positive 
results for depression in children and adolescents.31 It is 
also possible that the psychotherapies used with young 
patients with depression, which are largely adaptations 
of treatments developed for adults, might not be ideally 
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suited to the cognitive, behavioural, and emotional 
characteristics of young people, and that innovations in 
treatment design and content will be needed to produce 
stronger treatment effects.
In 2004, the FDA placed a boxed warning on anti­
depressants for risk of suicidal thoughts and behaviour 
in children and adolescents on the basis of results of 
clinical trials.32 In our analysis, suicidality data on 
psychological and combination interventions were, for 
the first time, systematically investigated using the same 
approach used for medication alone. We found that 
venlafaxine had a significantly increased risk for 
suicidality (suicidal behaviour or ideation) for young 
people, which is in line with previous reviews.10,11 Two US 
medical claims databases that contain data on 
221 028 young people with depression for the period 
2004–09 showed that, after accounting for the time 
varying effect of confounders, the apparent association 
between antidepressant use and suicide attempts and 
self­inflicted injury was diminished and not statistically 
significant.33 Antidepressant use by adolescents had 
previously been increasing but declined abruptly after 
the warnings were introduced.34 Our evidence linked 
venlafaxine alone to an increased effect on suicidal 
behaviour or ideation, which might be due to better 
reporting of venlafaxine data. Owing to the absence of 
reliable data on suicidality for many antidepressants, 
comprehensive assessment of the risk of suicidality for 
all interventions was not possible. Prescribers should 
closely monitor suicide risk when children and 
adolescents take any antidepressant drugs, particularly at 
the beginning of treatment.5
Our review has several limitations. First, according to 
the CINeMA assessment, the quality of most comparisons 
was low or very low. Many trials did not report adequate 
information about allocation concealment, and it is 
difficult to use a double­blind design for patients in trials 
of psychotherapy, which would affect the transitivity of 
the whole network and restricts the interpretation of 
these results.15 We did a sensitivity analysis excluding 
non­blinded psychotherapy trials, the findings of which 
were not materially different from those of the primary 
analysis. Additionally, different outcomes from the same 
trials can be a source of pharmaceutical marketing bias.35 
However, before the study, we established a hierarchy of 
informants of depressive rating scales, which could 
reduce this type of outcome bias. Second, in the network, 
we found some global and local inconsistencies in 
efficacy outcomes, but few in acceptability outcomes, 
perhaps because the proportion of patients who withdrew 
was a more consistently measured outcome across 
studies than efficacy, which was measured using various 
rating scales. Moreover, this inconsistency in efficacy 
outcomes might be a consequence of the decrease in 
antidepressant–placebo differences in antidepressant 
clinical trials in the past three decades, which could be 
explained by changes in study design.36 Although the 
meta­regression analyses of modifiers did not materially 
affect the outcomes, we found that some comparisons 
had relatively low or high values in the transitivity 
assessment; thus, we downgraded the confidence of 
these comparisons. Third, in order to support transitivity 
assumption in the network, the review was restricted to 
trials involving children and adolescents with depressive 
disorder. We excluded studies in which participants were 
described as having subsyndromal depressive symptoms, 
because anti de pressants are not recommended in this 
group of patients. They do, however, form a substantial 
proportion of the patients seen in real­world, clinical 
settings.37 We also excluded patients with psychotic or 
treatment­resistant depression. Augmentation therapy is 
usually required for these patients, and including them 
would have violated transitivity required of the network 
meta­analysis. Fourth, despite the Egger’s test showing 
no publication bias for most outcomes, we found some 
potential asymmetry of funnel plots in this network 
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meta­analysis. Thus, the clinical interpretation of these 
findings is limited by the potential bias from selective 
reporting. We did our best to retrieve all available 
unpublished information and contacted study authors 
for supple mentary data, but we cannot rule out the 
possibility that some unpublished studies are still 
missing.38 Fifth, the Restoring Study 329,39 which 
reanalysed the data and protocol of SmithKline 
Beecham’s Study 329,40 showed different and even 
opposite results of efficacy and tolerability of paroxetine 
and imipramine. We have selected the data from 
Restoring Study 329 for this review, but we could not 
assure the accuracy of the data in the other included 
trials. Although we have checked the published data with 
their protocols or trial register reports, we were not able 
to investigate these main outcomes at the individual 
patient level. Researchers and clinicians should recognise 
the potential biases in published studies, especially with 
regard to the potential barriers that have led to inaccurate 
reporting of harm outcomes.39 Sixth, antidepressants 
with different doses might produce different treatment 
effects.41 Although we included antidepressants without 
therapeutic dose ranges, we should consider the potential 
dose effects in this review. Moreover, various anti­
depressants have a wide range of half­lives, from 5 h to 
5 days. Anti depressants with a long half­life (ie, fluoxetine 
and paroxetine) need to be titrated over 3 or 4 weeks, 
whereas antidepressants with a short half­life (ie, 
venlafaxine) do not.42 These titrations might confuse the 
outcomes from the short trials. In this review, we have 
excluded trials with treatment duration of less than 
4 weeks, which could reduce the effect for the final 
analysis. Seventh, because of the paucity of information 
reported in the original studies, we were not able to 
quantify some outcomes, such as adverse events 
discontinuation and global functioning. Some of the 
adverse effects would also be expected in psychotherapy 
trials, including the emergence of new symptoms and 
strains in the patient­therapist relationship,43 however, 
few psychotherapy trials report data on adverse events 
and suicidality.44 The current report summarises evidence 
of efficacy and acceptability of active interventions when 
prescribed in acute treat ment. Relatively few studies 
addressed the issue of preventing relapse of depression 
in children and adolescents, and some of the adverse 
effects of anti depressants and response to psychotherapy 
occur over a prolonged period, meaning that positive 
results need to be interpreted with caution. Finally, there 
were some limitations in the network meta­analysis 
method. In this network meta­analysis, a small number 
of trials compared the same treatments, and the 
assumption of transitivity over various control conditions 
was under stated. These control conditions can lead to 
reduced network connectivity in network meta­analyses 
and therefore low statistical power.45 We excluded obser­
vational studies to decrease the hetero geneity in the 
network meta­analysis; however, obser vational studies 
can provide more information about real­world evidence 
on antidepressant effectiveness in the studied population 
group.46
Despite these limitations, the findings from this 
network meta­analysis represent the most comprehensive 
analysis of the available evidence. The findings suggest 
that fluoxetine (alone or in combination with CBT) might 
be considered the best option to treat acute symptoms in 
children and adolescents with major depression. Future 
guidelines and daily clinical decision making on the 
choice of interventions for acute treatment of young 
patients with depression should account for these results. 
Academia, industry, and study authors should collaborate 
to produce more research that analyses individual patient 
data in network meta­analyses. Such analyses will enable 
the prediction of personalised clinical outcomes, 
including specific side­effects, comparative efficacy at 
multiple timepoints, and different baseline severities.
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Figure 4: Forest plots of network meta-analysis
(A) Efficacy. (B) Acceptability. (C) Suicidality. Interventions were compared with pill placebo for efficacy and 
acceptability and with venlafaxine for suicidality. CBT=Cognitive-behavioural therapy. CrI=credible interval. 
OR=odds ratio. SMD=standardised mean difference. *Significant results.
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